Online citations, reference lists, and bibliographies.
← Back to Search

Limited Efficacy Of Imatinib Mesylate In Malignant Mesothelioma: A Phase II Trial.

A. Mathy, P. Baas, O. Dalesio, N. van Zandwijk
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Twenty-five patients with histologically proven malignant mesothelioma participated in a trial of imatinib mesylate (Glivec) with a starting dose of 400 mg per day taken orally, up to a maximal dose of 800 mg. No responses were observed in the patient group, while three patients showed prolonged (>6 months) stabilization of disease. The median survival time was 398 days (range 88-840); the median time to progression was 63 days (range 29-275). Side effects of the medication were mild and included edema, nausea, constipation and diarrhea. We conclude that further investigation with monotherapy imatinib in mesothelioma is not warranted.
This paper references
10.1016/J.PATBIO.2003.10.005
Mesothelioma pathogenesis, facts and expectations.
M. Jaurand (2005)
10.1200/JCO.2004.22.14_SUPPL.7200
A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM).
J. Villano (2004)
10.1056/NEJM200104053441402
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
B. Druker (2001)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
10.1097/01.MP.0000083647.69123.5C
c-Kit Is Not Expressed in Malignant Mesothelioma
A. Horvai (2003)
10.1016/S0046-8177(98)90066-1
Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders.
D. Arber (1998)
10.1097/00001622-200303000-00002
Predictive and prognostic factors in malignant pleural mesothelioma
P. Baas (2003)
10.1097/00129039-200303000-00009
Immunohistochemistry Frequently Detects c-Kit Expression in Pulmonary Small Cell Carcinoma and May Help Select Clinical Subsets for a Novel Form of Chemotherapy
F. Lonardo (2003)
10.1016/S0959-8049(02)80600-1
Pharmacology of imatinib (STI571).
E. Buchdunger (2002)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)



This paper is referenced by
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
on Novel Therapies
Andrew R. Haas (2013)
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
10.3747/CO.V15I2.251
Malignant mesothelioma: Canadian perspective and research directions
C. Lee (2008)
10.3389/fonc.2011.00022
Investigational Approaches for Mesothelioma
V. Surmont (2011)
10.18632/genesandcancer.129
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
Ombretta Melaiu (2017)
Treating Malignant Pleural Mesothelioma : an update on the situation at the dawn of 2014
(2019)
10.1097/JTO.0b013e3181834f66
Recent Advances in the Treatment of Malignant Pleural Mesothelioma
S. Ramalingam (2008)
10.1007/978-3-642-10862-4_8
Chemotherapy and radiotherapy for mesothelioma.
X. Dhalluin (2011)
10.1158/1078-0432.CCR-07-1388
Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
P. Bertino (2008)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.17925/OHR.2008.04.1.60
Malignant Pleural Mesothelioma—A Current Review
Marc S. Ballas (2008)
10.1016/S1877-1203(11)70138-0
Cibler aussi le mésothéliome pleural malin et le cancer bronchique à petites cellules
L. Greillier (2011)
10.2217/fon.09.7
Malignant pleural mesothelioma.
R. Stahel (2009)
10.1016/J.EJCA.2006.07.011
Biology and management of malignant pleural mesothelioma.
P. Zucali (2006)
10.2174/9781681081946116010023
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
Tommaso Claudio Mineo and Vincenzo Ambrogi (2016)
10.4161/cbt.4.11.2253
Activating mutations in c-KIT and PDGFRα are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes
Kk Burger (2005)
10.1016/j.ccm.2012.12.005
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
A. Haas (2013)
Malignantpleuralmesothelioma: currenttreatmentsandemerging drugs
Carmen Belli (2009)
10.2217/fon.12.14
Systemic treatment of malignant pleural mesothelioma.
F. Grosso (2012)
10.1111/IGC.0b013e3181a80bb5
Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor &agr;
M. Candelaria (2009)
10.4236/JCT.2014.512116
Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Advanced Malignant Mesothelioma: A Strategy for Improved Survival
S. Burzynski (2014)
10.1517/14728210903074563
Malignant pleural mesothelioma: current treatments and emerging drugs
C. Belli (2009)
10.1158/1078-0432.CCR-11-2259
Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma
M. Carbone (2011)
10.1016/J.HOC.2005.09.010
An overview of chemotherapy for mesothelioma.
L. Krug (2005)
10.1016/j.canlet.2008.02.018
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
H. Ogino (2008)
10.1007/978-2-287-99041-0_20
Mésothéliome pleural malin
E. Bergot (2009)
10.1586/14737140.8.2.293
Current concepts in malignant pleural mesothelioma
A. Kaufman (2008)
10.1517/14656560802631285
Chemotherapy of malignant pleural mesothelioma
P. Bertino (2009)
10.4081/MONALDI.2010.302
Treatment of malignant pleural mesothelioma: current status and future directions.
X. Dhalluin (2010)
10.4137/BMI.S0
Expression of Cancer-Associated Molecules in Malignant Mesothelioma
B. Davidson (2007)
10.1158/1078-0432.CCR-17-1172
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition
J. Quispel-Janssen (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar